Amantadine in the Treatment of Sexual Dysfunction Associated with Selective Serotonin Reuptake Inhibitors

Shrivastava, Ram; Shrivastava, Sarita; Overweg, Norbert I.A.; Schmitt, Monica M.

doi:10.1097/00004714-199502000-00014

Cited by 55 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reported effective doses have ranged between 100–400 mg taken either on a daily or as-needed basis. Shrivastava et al (45) successfully treated six male patients, who were experiencing ejaculatory difficulty while taking paroxetine, with amantadine. Amantadine was given in divided doses of 200 mg twice daily and 400 mg daily.…”

Section: Amantadinementioning

confidence: 99%

The drug treatment of delayed ejaculation

Abdel‐Hamid¹,

Elsaied²,

Mostafa³

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

Delayed ejaculation (DE) is an uncommon and a challenging disorder to treat. It is often quite concerning to patients and it can affect psychosocial well-being. Here we reviewed how DE is treated pharmacologically .We also highlighted specific settings where drugs could be introduced to medical practice. Electronic databases were searched from 1966 to February 2016, including PubMed MEDLINE, EMBASE, EBCSO Academic Search Complete, Cochrane Systematic Reviews Database, and Google Scholar using key words; delayed ejaculation, retarded ejaculation, inhibited ejaculation, drugs, treatment, or pharmacology. To achieve the maximum sensitivity of the search strategy and to identify all studies, we combined “delayed ejaculation” as Medical Subject Headings (MeSH) terms or keywords with each of “testosterone” or “cabergoline” or “bupropion” or “amantadine” or “cyproheptadine” or “midodrine” or “imipramine” or “ephedrine” or “pseudoephedrine” or “yohimbine” or “buspirone” or “oxytocin” or “bethanechol” as MeSH terms or keywords. There are a number of drugs to treat patients with DE including: testosterone, cabergoline, bupropion, amantadine, cyproheptadine, midodrine, imipramine, ephedrine, pseudoephedrine, yohimbine, buspirone, oxytocin, and bethanechol. Although there are many pharmacological treatment options, the evidence is still limited to small trials, case series or case reports. Review of literature showed that evidence level 1 (Double blind randomized clinical trial) studies were performed with testosterone, oxytocin, buspirone or bethanechol treatment. It is concluded that successful drug treatment of DE is still in its infancy. The clinicians need to be aware of the pathogenesis of DE and the pharmacological basis underlying the use of different drugs to extend better care for these patients. Various drugs are available to address such problem, however their evidence of efficacy is still limited and their choice needs to be individualized to each specific case.

show abstract

Section: Amantadinementioning

confidence: 99%

The drug treatment of delayed ejaculation

Abdel‐Hamid¹,

Elsaied²,

Mostafa³

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…Several authors have reported an effect for amantadine (100 mg administered 5-6 hours before coitus) in the reversal of SSRI-induced anorgasmia [67][68][69]. Thus, a potential role in reversing organic DE could be hypothesized and should be investigated.…”

Section: Drugs For the Treatment Of Dementioning

confidence: 99%

Neurogenic Ejaculatory Disorders: Focus on Current and Future Treatments

Calabrò

Polimeni²,

Casella

et al. 2011

RPCN

View full text Add to dashboard Cite

Ejaculation is a complex and still poorly understood neurological mechanism, at both spinal and cerebral levels as it is closely associated with orgasm. Physiologically, ejaculation is defined as the expulsion of seminal fluid from the urethral meatus and consists of two phases, namely emission and expulsion. Ejaculation is mediated by a spinal control center, referred to as a spinal pattern generator that coordinates sympathetic, parasympathetic and motor (somatic) outflows, integrating the latter with the inputs from the supraspinal sites in brainstem, hypothalamus and preoptic area. Premature ejaculation (PE) is the most common sexual dysfunction among young men, and it has been considered mostly psychogenic in origin, although it can be associated to diverse urological and neurological diseases. On the contrary, retrograde ejaculation and anejaculation are predominantly related to organic causes, particularly to neurogenic ones. Since ejaculation is mostly a spinal reflex, it is comprehensible that ejaculatory disorders are more frequent in spinal cord injury than in other neurological disorders. Over the past decades, research has focused on PE, and evidence from clinical studies showed a beneficial effect of antidepressants for the treatment of men with PE. Other ejaculatory disorders, especially painful ejaculation, have been less investigated and the proper therapy is still controversial. Aim of this review is to provide a comprehensive description of both currently available treatments and most promising future therapies, including assigned patents, for the neurogenic ejaculatory disorders.

show abstract

“…Treatment of hyperprolactinemia (Mattox et al, 1986) and Parkinson's disease (Rektorova et al, 2003) with pergolide also appears to result in a decrease in depressive symptoms. There is also anecdotal evidence to suggest a potential antidepressant role for amantadine when used in conjunction with standard antidepressants in MDD (Rogóz et al, 2003b;Stryjer et al, 2003), and case reports of amantadine used to alleviate SSRI-emergent sexual dysfunction (Balogh et al, 1992;Shrivastava et al, 1995). A double-blind study revealed greater improvement than with placebo in residual fatigue but not sexual dysfunction when amantadine was added to the SSRI regimen of women with MDD who had responded to SSRIs (Michelson et al, 2000b).…”

Section: Dopaminergic Agentsmentioning

confidence: 99%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

Amantadine in the Treatment of Sexual Dysfunction Associated with Selective Serotonin Reuptake Inhibitors

Cited by 55 publications

References 2 publications

The drug treatment of delayed ejaculation

The drug treatment of delayed ejaculation

Neurogenic Ejaculatory Disorders: Focus on Current and Future Treatments

Monoaminergic‐based Pharmacotherapy for Depression

Contact Info

Product

Resources

About